FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118791311> ?p ?o ?g. }

• W3118791311 abstract "To address the sub-optimal treatment outcomes among patients with multidrug-resistant (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), the National TB Programme in Belarus started using new drugs such as bedaquiline and delamanid in 2015-16. In this study, we assessed cardiovascular safety and effectiveness (culture conversion, treatment outcomes and post-treatment recurrence) of delamanid-containing regimens among adults (>18 years) with MDR-TB or XDR-TB from June 2016 to February 2018. This was a nationwide cohort study involving analysis of routinely collected programme data from the national and six regional TB hospitals. Cardiovascular adverse events (AEs) were classified as serious or not, based on international guidelines. We conducted Cox proportional hazards regression and calculated adjusted hazards ratio(aHR) and 95% confidence intervals(CI) to evaluate factors associated with AEs and unsuccessful treatment outcomes (death, failure and lost-to-follow-up). Of 125 patients enrolled (35, 28% females; mean age 43 years), 85(68%) had XDR-TB. All the patients received delamanid and 20 patients received both delamanid and bedaquiline. Cardiovascular AEs (177 episodes in total), were observed in the majority (73%) of patients but were mild and managed easily. The most common cardiovascular AEs were QTcF prolongation (64/177, 36%) and other electrocardiography (ECG) abnormalities (40/177, 23%). There were two instances of serious AEs leading to death, both of which were not related to delamanid. In multivariable analysis, male sex (aHR 0.72; 95% CI 0.51-0.99), and baseline ECG abnormalities (aHR 1.68; 95% CI 1.19-2.36) were associated with cardiovascular AEs. Median time to culture conversion was 1.1 months (interquartile range: 1.0-2.1). Culture conversion was observed in 115 (92%) patients at six months of treatment and 110 (88%) completed the treatment successfully. Loss to follow-up, failure and death were observed in 6%, 4% and 2% patients respectively. Among those assessed at 12 months post-treatment (n=33), recurrence was seen in one patient. The only factor associated with unsuccessful treatment outcomes in multivariable analysis was baseline Hepatitis C co-infection (aHR 3.61; 95% CI 1.09-11.95). In conclusion, treatment using delamanid-containing regimens was effective and had a favourable safety profile. We hope our findings inform the development of national clinical guidelines and scale-up of new drugs in other countries." @default.
• W3118791311 created "2021-01-18" @default.
• W3118791311 creator A5001861047 @default.
• W3118791311 creator A5012041911 @default.
• W3118791311 creator A5015400537 @default.
• W3118791311 creator A5035829207 @default.
• W3118791311 creator A5046546536 @default.
• W3118791311 creator A5055892113 @default.
• W3118791311 creator A5066850183 @default.
• W3118791311 creator A5072754443 @default.
• W3118791311 creator A5084898120 @default.
• W3118791311 creator A5085130303 @default.
• W3118791311 date "2021-01-14" @default.
• W3118791311 modified "2023-10-10" @default.
• W3118791311 title "Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18" @default.
• W3118791311 doi "https://doi.org/10.4081/monaldi.2021.1647" @default.
• W3118791311 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33470081" @default.
• W3118791311 hasPublicationYear "2021" @default.
• W3118791311 type Work @default.
• W3118791311 sameAs 3118791311 @default.
• W3118791311 citedByCount "2" @default.
• W3118791311 countsByYear W31187913112022 @default.
• W3118791311 crossrefType "journal-article" @default.
• W3118791311 hasAuthorship W3118791311A5001861047 @default.
• W3118791311 hasAuthorship W3118791311A5012041911 @default.
• W3118791311 hasAuthorship W3118791311A5015400537 @default.
• W3118791311 hasAuthorship W3118791311A5035829207 @default.
• W3118791311 hasAuthorship W3118791311A5046546536 @default.
• W3118791311 hasAuthorship W3118791311A5055892113 @default.
• W3118791311 hasAuthorship W3118791311A5066850183 @default.
• W3118791311 hasAuthorship W3118791311A5072754443 @default.
• W3118791311 hasAuthorship W3118791311A5084898120 @default.
• W3118791311 hasAuthorship W3118791311A5085130303 @default.
• W3118791311 hasBestOaLocation W31187913111 @default.
• W3118791311 hasConcept C126322002 @default.
• W3118791311 hasConcept C142724271 @default.
• W3118791311 hasConcept C197934379 @default.
• W3118791311 hasConcept C201903717 @default.
• W3118791311 hasConcept C207103383 @default.
• W3118791311 hasConcept C2776301714 @default.
• W3118791311 hasConcept C2777025531 @default.
• W3118791311 hasConcept C2777107064 @default.
• W3118791311 hasConcept C2777768864 @default.
• W3118791311 hasConcept C2777975735 @default.
• W3118791311 hasConcept C2780544761 @default.
• W3118791311 hasConcept C2781069245 @default.
• W3118791311 hasConcept C44249647 @default.
• W3118791311 hasConcept C50382708 @default.
• W3118791311 hasConcept C71924100 @default.
• W3118791311 hasConcept C72563966 @default.
• W3118791311 hasConceptScore W3118791311C126322002 @default.
• W3118791311 hasConceptScore W3118791311C142724271 @default.
• W3118791311 hasConceptScore W3118791311C197934379 @default.
• W3118791311 hasConceptScore W3118791311C201903717 @default.
• W3118791311 hasConceptScore W3118791311C207103383 @default.
• W3118791311 hasConceptScore W3118791311C2776301714 @default.
• W3118791311 hasConceptScore W3118791311C2777025531 @default.
• W3118791311 hasConceptScore W3118791311C2777107064 @default.
• W3118791311 hasConceptScore W3118791311C2777768864 @default.
• W3118791311 hasConceptScore W3118791311C2777975735 @default.
• W3118791311 hasConceptScore W3118791311C2780544761 @default.
• W3118791311 hasConceptScore W3118791311C2781069245 @default.
• W3118791311 hasConceptScore W3118791311C44249647 @default.
• W3118791311 hasConceptScore W3118791311C50382708 @default.
• W3118791311 hasConceptScore W3118791311C71924100 @default.
• W3118791311 hasConceptScore W3118791311C72563966 @default.
• W3118791311 hasIssue "1" @default.
• W3118791311 hasLocation W31187913111 @default.
• W3118791311 hasOpenAccess W3118791311 @default.
• W3118791311 hasPrimaryLocation W31187913111 @default.
• W3118791311 hasRelatedWork W2081932779 @default.
• W3118791311 hasRelatedWork W2541813176 @default.
• W3118791311 hasRelatedWork W2790218761 @default.
• W3118791311 hasRelatedWork W2799631683 @default.
• W3118791311 hasRelatedWork W3034335227 @default.
• W3118791311 hasRelatedWork W3109425014 @default.
• W3118791311 hasRelatedWork W3123210133 @default.
• W3118791311 hasRelatedWork W4293435900 @default.
• W3118791311 hasRelatedWork W4309646522 @default.
• W3118791311 hasRelatedWork W4324279384 @default.
• W3118791311 hasVolume "91" @default.
• W3118791311 isParatext "false" @default.
• W3118791311 isRetracted "false" @default.
• W3118791311 magId "3118791311" @default.
• W3118791311 workType "article" @default.